Research Areas

A Study Comparing Safety and Efficacy of Three Doses of an Infused Investigational Medication to Placebo Given by Continuous Subcutaneous Infusion in Combination with Metformin and Sulfonylurea Over 12 Weeks in Patients with Type 2 Diabetes Mellitus

A Randomized, Double-blind, Dose ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of an Investigational Medication in Subjects with Type 2 Diabetes

Dose Finding, Efficacy, and Safety of an Investigational Medication in Subjects with Type 2 Diabetes

Efficacy and Safety of an investigational medication Compared with Subcutaneous Human Insulin Therapy in Adult Subjects with Type 2 Diabetes Mellitus: A Two-year, Outpatient, Open-Label, Parallel-Group Comparative Trial

A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of an investigational medication Given Two Times a Day in Subjects with Type 2 Diabetes Mellitus Treated With Sulfonylurea Alone

A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of an Investigational Medication Given Two Times a Day in Subjects with Type 2 Diabetes Mellitus Treated With Metformin Alone

70/30 (biphasic insulin aspart 70/30) bid vs. (insulin glargine): A Multicenter, Randomized, Open-Label, Parallel Group Study in Subjects with type 2 Diabetes Inadequately Treated with OAD therapy

A Randomized, Open-Label, Parallel-Group, Multicenter Study to Determine the Efficacy and Long-Term Safety of An Investigational Medication Compared With Insulin in Subjects with Type 2 Diabetes Mellitus.

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of An Investigational Medication When Used in Combination with Pioglitazone with or without Metformin in Subjects with Type 2 Diabetes Mellitus.

A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of An Investigational Medication Administered in Combination With Metformin and Glimepiride Compared With Metformin Plus Glimepiride and Placebo and With Metformin Plus Glimepiride and Pioglitazone in Subjects with Type 2 Diabetes Mellitus.

A 52-Week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-Target Trial Comparing Efficacy and Safety of An Investigational Insulin and Insulin Glargine Both Administered Once Daily in a Basal-Bolus Regimen with Insulin Aspart as Mealtime Insulin +/- Treatment with Metformin, +/- Pioglitazone in Subjects with Type 2 Diabetes Currently Treated with Insulin Qualifying for Intensified Treatment

A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multi-Center Study to Evaluate the Safety and Efficacy of An Investigational Medication in Patients with Type 2 Diabetes Mellitus on Background Treatment with Glimepiride With or Without Metformin

A Phase III Randomized, Double-Blind, Placebo-Controlled, Parallel Group Efficacy and Safety Study of An Investigational Medication, Administered Orally Once Daily for at least 52 Weeks in Type 2 Diabetic Patients in Combination with Basal Insulin Therapy

A Trial Comparing Efficacy and Safety of An Investigational Medication and Insulin Glargine in Subjects With Type 2 Diabetes

A Phase 2 Study of An Investigational Medication Compared with Insulin Glargine in the Treatment of Type 2 Diabetes Mellitus.

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Safety and Efficacy of An Investigational Medication in Subjects with Type 2 Diabetes Mellitus on Stable Metformin Monotherapy

The Effect of An Investigational Medication on Blood Pressure and Heart Rate as Assessed by Ambulatory Blood Pressure Monitoring in Patients with Type 2 Diabetes Mellitus.

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of An Investigational Medication Compared with Placebo in the Treatment of Older Subjects with Type 2 Diabetes Mellitus Inadequately Controlled on Glucose Lowering Therapy.

The Impact of An Investigational Medication versus Insulin Glargine Both in Combination with Insulin Lispro for the Treatment to Target of Type 2 Diabetes Mellitus.

Safety of Novolog in CSH compared to basal/ bolus therapy with Novolog and Lantus in Patients with Type 1 Diabetes Previously Treated with CSII; a Randomized, Cross-Over Trial.